A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE-AGENT MLN0128 AND THE COMBINATION OF MLN0128+MLN1117 COMPARED WITH EVEROLIMUS IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA THAT HAS PROGRESSED ON VASCULAR ENDOTHELIAL GROWTH FACTOR-TARGETED THERAPY
- Registry ID
- C31005
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MILLENNIUM PHARMACEUTICALS INC
- Start date
- 2016-10-28
- Completion date
- 2020-10-13
- Last update
- 2016-04-13
Conditions
- RENAL CELL CARCINOMA METASTATIC
Related clinical trials
- A PHASE 2, SINGLE-ARM, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB PLUS LENVATINIB IN PARTICIPANTS WITH FIRST LINE ADVANCED/METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC) (KEYNOTE-B61)
- A PHASE III RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH AXITINIB VERSUS SUNITINIB MONOTHERAPY AS A FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-426)
- A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA) VERSUS SUNITINIB (SUTENT) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
- A MULTI-CENTER, OPEN LABEL, RANDOMIZED PHASE 2 STUDY OF AGS-16C3F VS AXITINIB IN METASTATIC RENAL CELL CARCINOMA
- A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA
View on source registry